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Abstract N-Acetylneuraminic acid is a main constituent of 
glycoproteins and gangliosides. In many membrane-bound 
receptors it is the target for external stimuli. The key enzyme 
for its biosynthesis is the bifunctional enzyme UDP-N-acetyl- 
glucosamine-2-epimerase/N-acetylmannosamine kinase,catalys- 
ing the first two steps of the biosynthesis in the cytosol. The rat 
enzyme was previously isolated and characterised. In this report 
we present he corresponding human cDNA sequence, compare it 
with the primary structure of the rodent enzyme, and report the 
analysis of its expression in different human tissues and cell lines. 
© 1999 Federation of European Biochemical Societies. 
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illustrated by the observation that in hepatoma activity of 
the UDP-GlcNAc-2-epimerase is dramatically reduced [16]. 
Recently, the 2-epimerase was found to be a major determi- 
nant of cell surface sialylation in haematopoietic cell lines [17]. 
The clinical relevance of the enzyme was demonstrated by the 
observation that the basic defect in sialuria has been identified 
as the loss of feedback control of UDP-GlcNAc-2-epimerase 
by CMP-N-acetylneuraminic a id with resultant overproduc- 
tion of sialic acid [18,19]. Therefore characterisation of the 
human UDP-GlcNAc-2-epimerase/ManAc kinase could give 
new insights into this or possibly other human diseases. In 
this study we isolated, cloned and sequenced the cDNA 
from human liver. The deduced primary structure revealed 
high sequence similarity to the rodent enzymes, indicating 
high evolutionary conservation. Differential tissue and cell 
line expression was demonstrated by mRNA analysis. 
1. Introduction 
In eukaryotic organisms N-acetylneuraminic a id is a ter- 
minal component of glycan structures bound to proteins and 
gangliosides [1,2]. It is considered a molecular determinant of 
specific biological functions [3] such as cellular adhesion [4-6], 
formation or masking of recognition determinants [7-10] and 
stabilisation of glycoprotein structures [11,12]. Recently it was 
shown that the two enzymes initiating the biosynthesis of 
Neu5Ac, UDP-N-acetylglucosamine-2-epimerase (UDP- 
GlcNAc-2-epimerase) and N-acetylmannosamine kinase 
(ManNAc kinase) (EC 5.1.3.14/EC 2.7.1.60) are parts of one 
bifunctional enzyme. This 79 kDa protein assembles to a 
dimer or hexamer. The hexameric structure represents both 
activities, the formation of N-acetylmannosamine and UDP 
from UDP-N-acetylglucosamine and the subsequent phos- 
phorylation of N-acetylmannosamine (ManNAc), whereas 
the dimer catalyses only the phosphorylation of N-acetyl- 
mannosamine [13]. In rodents, the highest levels of expression 
and activity are found in liver, salivary gland and intestinal 
mucosa. In other organs the enzyme is expressed in smaller 
amounts paralleled by lower total enzyme activities [14] The 
UDP-GlcNAc-2-epimerase/ManNAc kinase is expressed at 
early stages during development [15], indicating its importance 
during organogenesis. The biological significance is further 
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2. Materials and methods 
2.1. Materials' 
Unless otherwise stated, chemicals and reagents were obtained from 
Sigma-Aldrich, Deisenhofen, Germany. Enzymes were obtained from 
Life Technologies, Karlsruhe, Germany. Escherichia coli HB 101 and 
XL-1 blue were obtained from Stratagene, La Jolla, CA, USA and 
E. coli INVc~F' from lnvitrogen, Leek, The Netherlands. 
2.2. RT-PCR, cDNA library screening and 5" RACE 
DNA and RNA were prepared and analysed according to standard 
procedures [20]. Isolation of cDNA encoding the human UDP- 
GlcNAc-2-epimerase was done using a combination of RT-PCR, 
cDNA library screening and 5' RACE. 
Poly(A) + RNA from human liver (Clontech, Heidelberg, Germa0y) 
was used for RT-PCR. It was transcribed to cDNA using oligo(dt) 
primer and superscript reverse transcriptase (Life Technology, Karls- 
ruhe, Germany) at 37°C for 60 min according to the manufacturer's 
instructions. The PCR reaction was performed under standard con- 
ditions [21]. For that UDP-GlcNAc-2-epimerase-specific primers ac- 
cording to the published rat sequence [14] were annealed to the human 
liver cDNA and incubated with Taq polymerase (Perkin Elmer, 
Branchburg, USA) over 25 cycles (30 s 94°C; 60 s 50°C; 90 s 
72°C). Amplification products were analysed by horizontal agarose 
gel electrophoresis, isolated from the gel and cloned into the 
pCR2.1 vector (Invitrogen, Leek, The Netherlands) and sequenced. 
A human liver cDNA library (oligo(dt)- and random-primed cDNA 
ligated into Uni 0~ZAP XR, Stratagene, La Jolla, CA, USA) was 
screened by hybridisation with a rat coding region probe according 
to standard procedures. Labelling of the rat DNA fragment was done 
by [c~-32p]dATP incorporation using a random priming labelling kit 
(Amersham-Buchler, B aunschweig, Germany). A total of 5 × 10 s pla- 
ques were plated, lifted to nitrocellulose filters and hybridised to the 
labelled probe under stringent conditions overnight at 42°C. The 
phagemid pBluescript II SK was excised from positive phages by 
in vivo excision using the helper phage R408 (Stratagene, La Jolla, 
CA, USA) according to the manufacturer's protocol, cDNA inserts 
were analysed in horizontal agarose gel electrophoresis and sequenced 
as described in Section 2.3. 
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Fig. 1. Schematic presentation of cDNA fragments obtained by 
PCR and library screening. In the upper part of the figure the 
whole cDNA encoding the human UDP-GlcNAc-2-epimerase/Man- 
NAc kinase is shown with indicated restriction enzyme cleavage 
sites. The start and stop codons are marked by arrows. In the lower 
part of the figure the obtained lambda cDNA clones (kLD4-1. 
XD1), the PCR fragments using primer specific for the correspond- 
ing rat sequence (PCR.a-g) and the PCR fragments from 5' RACE 
priming (Race.I, II) are shown. The position relative to +1 of the 
coding region is indicated. All fragments were sequenced as de- 
scribed in Section 2. Parts of the bars indicated in grey show high 
similarity to the rat sequence. 
Elongation of the 5' cDNA terminus was performed using a 
5'RACE kit (Life Technologies, Karlsruhe, Germany) according to 
the manufacturer's manual. As starting material for RT-PCR, 5 p_g 
human liver poly(A) + RNA (Clontech, Heidelberg, Germany) were 
primed with human UDP-GlcNAc-2-epimerase-specific primers. Ob- 
tained cDNA was tailed with poly-dCTP using the Terminal deoxy- 
nucleotide Transferase (TdT). Subsequent amplification was done 
with an anchor primer containing an oligo(dG) sequence and a second 
internal UDP-GlcNAc-2-epimerase-specific primer. PCR products of 
the polymerase chain reactions were analysed in horizontal agarose 
gel electrophoresis, cloned into the pCR2.1 vector (lnvitrogen, Leek, 
The Netherlands) and sequenced as described in Section 2.3. 
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2.3. Cloning and sequencing 
Using the TA-cloning kit (Invitrogen, San Diego, CA, USA), ap- 
proximately 50 ng of each reaction product were ligated directly into 
the pCR II vector (Invitrogen, San Diego, CA, USA). Ligated DNA 
was transformed into E. coli HB101 or INVc~F'. Positive clones were 
identified by restriction analysis and sequencing. Sequencing accord- 
ing to Sanger et al. [22] was performed either with double-stranded 
plasmid DNA using [c~YS]dATP (Hartmann Analytic, Braunschweig, 
AA CTC TAT TTT AAG AAC CTC TCA AAA CGA AAC AAG CAA ATC -i 
Met  GIu Lys ASh G ly  Asn  Asn  Arg  Lys Leu Arg Val  Cys Val  A la  Thr  Cys ASh Arg Ala 20 
ATG GAG AAG AAT GGA AAT AAC CGA AAG CTG CGG GTT TGT GTT GCT ACT TGT AAC CGT GCA 60 
Asp  Tyr Sel  Lys Leu Ala Pro I le Met  Phe Gly I le Lys Thr Glu Pro GIu Phe Phe G lu  40 
GAT TAT TCT AAA CTT GCC CCG ATC ATG %~fT GGC A'fT AAA ACC GAA CCT GAG TTC TTT GAA 120 
Leu Asp Val  Val  Val Leu Gly Ser His Leu I le Asp  Asp  Tyr Gly  ASh Thr  Tyr Axg Met  60 
CTT  GAT GTT GTG GTA CTT CCC TCT CAC CTG ATA GAT GAC TAT GGA AAT ACA TAT CGA ATG 180 
I le Glu Gln Asp  Asp  Phe Asp Zle Asn  Thr Arg  Leu His Thr  I le Val  Axg  Gly Glu Asp  80 
ATT  GAA CAA GAT GAC TTT GAC ATT AAC ACC AGG CTA CAC ACA ATT GTG AGG GGA GAA GAT 240 
Glu Ala  A la  Met  Val  GIu Ser Val  G ly  Leu Ala Leu Val Lys Leu Pro Asp  Val Leu ASh 100 
GAG C~A GCC ATG GTG GAG TCA GTA GGC CTG GCC CTA GTG AAG CTG CCA GAT GTC CTT AAT 300 
Arg  Leu Lys Pro Asp  Ile Met  I le Val His Gly  Asp  Axg  Phe Asp  Ala Leu  Ala Leu A la  120 
CGC CTG AAG CCT GAT ATC ATG ATT GTT CAT GGA GAC AGG TTT GAT GCC CTG GCT CTG GCC 360 
Thr  Ser A la  A la  Leu Met  ASh Ile Arg  I le Leu His I le GIu Gly Gly  GIu Val  Set G ly  140 
ACA TCT GCT GCC TTG ATG AAC ATC CGA ATC CTT CAC ATT  GAA GGT GGG GAA GTC AGT GGG 420 
Thr  I le Asp Asp  Set I le Arg His  A la  I le  Thr  Lys Leu A la  His Tyr  His  Val  Cys Cys 160 
ACC ATT GAT GAC TCT ATC AGA CAT CCC ATA ACA AAA CTG GCT CAT TAT CAT GTG TGC TGC 480 
Thr  Axg Ser A la  GIu Gln His Leu I le Set Met  Cys Glu Asp  His Asp  Arg  I le Leu Leu 180 
ACC CGC AGT GCA GAG CAG CAC CTG ATA TCC ATG TGT GAG GAC CAT GAT CGC ATC CT~ TTG 540 
A la  Gly  Cys Pro Ser Tyr Asp  Lys Leu Leu Ser A la  Lys Asn Lys Asp  Tyr  Met  Ser I le 200 
GCA CCC TCC CCT TCC TAT GAC AAA CTT CTC TCA GCC AAG AAC AAA GAC TAC ATG AGC ATC 600 
I le Arg  Met  Trp Leu  Gly Asp  Asp Val  Lys Ser Lys Asp  Tyr  I le Val  A la  Leu Gln His  220 
ATT  CGC ATG TGG CTA CGT GAT GAT GTA AAA TCT AAA GAT TAC ATT  GTT GCA CTA CAG CAC 660 
Pro  Val  Thr  Thr  Asp  Ile Lys His Ser I le Lys Met  Phe Glu Leu Thr  LeU Asp A la  Leu 240 
CCT GTG ACC ACT GAC ATT  AAG CAT TCC ATA AAA ATG TTT  GAA THA ACA TTG GAT GCA CTT 720 
I le Ser Phe ASh Lys Arg Thr Leu Val  Leu Phe Pro Asn Ile Asp  A la  Gly  Ser Lys G lu  260 
ATC TCA TTT AAC AAG CGG ACC CTA GTC CTG TTT CCA AAT ATT GAC GCA GGG AGC AAA GAG 780 
Met  Val  Axg Val  Met  Axg Lys Lys Gly I le Glu His His Pro Asn  Phe Axg Ala Val Lys 280 
ATG GTT CGA GTG ATG CGG AAG AAG GGC ATT GAG CAT CAT CCC AAC TTT CGT CCA GTT AAA 840 
His  Val Pro Phs Asp  Gln Phe Ile Gln Leu Val  A la  His A la  Gly  Cys Met  I le G ly  ASh 300 
CAC GTC CCA TTT GAC CAG TTT ATA CAG TTG GTT GCC CAT GCT GGC TGT AHG ATT GGG AAC 900 
Set  Ser Cys Gly Va l  Arg Glu Val  G ly  A la  Phe G ly  Thr  Pro Val  I le ASh Leu Gly Thr  320 
AC42 AGC TGT GGG GTT CGA GAA GTT GGA GCT TTT GGA ACA CCT GTG ATC AAC CTG GGA ACA 960 
Arg  Gln I le Gly  Arg  GIu Thr G ly  Glu ASh Val  Leu His Val  Arg  Asp  A la  Asp  Thr  G ln  340 
CGT CAG ATT GGA AGA GAA ACA GGG GAG AAT GTT CTT CAT GTC CGG GAT GCT GAC ACC CAA 1020 
Asp  Lys I le Leu  Gln Ala  Leu His Leu  Gln Phe G ly  Lys Gln Tyr  Pro Cys Ser  Lys I le 360 
GAC AAA AHA TTG CAA GCA CTG CAC CTT CAG TTT GGT AAA CAG TAC CCT TGT TCA AAG ATA 1080 
Tyr  G ly  Asp  G ly  Asn  Ala Val  Pro Arg  I le Leu Lys Phe Leu Lys Ser I le Asp  Leu G ln  380 
TAT GCG GAT GGA AAT GCT GTT CCA AGG ATT TTG AAG TTT CTC AAA TCT ATC GAT CTT CAA 1140 
G Iu  Pro Leu G ln  Lys Lys Phe Cys Phe Pro Pro Val  Lys Glu ASh Ile Ser  Gln Asp  zle 480 
GAG CCA CTG CAA AAG AAA TTC TGC TTT CCT CCT GTG AAG GAG AAT ATC TCT CAA GAT ATT 12O0 
Asp  His I le Leu Glu Thr Leu Ser A la  Leu A la  Val  Asp  Leu Gly Gly  Thr  ASh Leu Arg  420 
GAC CAT ATT  CTT GAA ACT CTA AGT GCC TTG GCC GTT GAT CTT GCC GGG ACG AAC CTC CGA 1260 
Va l  Ala  I le Val  Ser Met  Lys G ly  GIu I le Val Lys Lys Tyr Thr  Gln Phe Asn Pro Lys 440 
GTT CCA ATA GTC AGC ATG AAG GGT GAA ATA GTT AAG AAG TAT ACT CAG TTC AAT CCT AAA 1320 
Thr  Tyr GIu Glu Arg  I le ASh Leu Ile Leu Gln Met  Cys Val  Glu A la  A la  A la  Glu A la  460 
ACC TAT GAA GAG AGG ATT AAT TTA ATC CTA CAG ATG TGT GTG GAA GCT GCA GCA GAA GCT 1380 
Va l  Lys Leu ASh Cys Arg I le Leu  Gly Val  Gly  I le Ser Thr Gly Gly  Arg  Val  Asn  Pro 480 
GTA AAA CTG AAC TGC AGA ATT  TTG GGA GTA GGC ATT TCC ACA GGT GGC CGT GTA AAT CCT 1440 
Arg  GIu Gly I le Val  Leu His Ser Thr  Lys Leu I le Gln Glu Trp Asn  Ser  Val  Asp  Leu  500 
CGG GAA GGA ATT  GTG CTG CAT TCA ACC AAA CHG ATC CAA GAG TGG AAC TCT GTG GAC CTT 1500 
Arg  Thr Pro Leu  Ser  Asp Thr  Leu His Leu Pro Va l  Trp Val  Asp Asn  Asp  Gly Asn  Cys 520 
AGG ACC CCC CTT TCT GAC ACT TTG CAT CTC CCT GTG TGG GTA GAC AAT GAT GGC AAC TGT 1580 
Ala A la  Leu Ala Glu Axg Lys Phe Gly Gln Gly Lys Gly Leu G lu  Asn Phe Val  Thr  Leu 540 
GCT CCC CTG GCG GAA AGG AAA TTT GGC CAA GGA AAG GGA CTG GAA AAC TTT C92T ACA CTT 1620 
I le Thr  Gly  Thr  Gly  I le Gly  Gly  Gly  I le I le His Gln His GIU Leu l le His  Gly Ser 560 
ATC ACA GGC ACA GGA ATC GGT GGT GGA ATT  ATC CAT CAG CAT GAA TTG ATC CAC GGA ACC 1680 
Ser  Phe Cys A la  A la  G lu  LeU Gly His  Leu Va l  Val  Set Leu Asp  Gly Pro Asp  Cys Ser 580 
TCC TTC TGT CCT GCA GAA CTG GGC CAC CTT G~T GTG TCT CTG GAT GGG CCT GAT TGT TCC 1740 
Cys Gly Ser His Gly  Cys I le Glu A la  Tyr  A la  Set Gly  Met  A la  Leu Gln Axg  Glu A la  600 
TGT GGA AGC CAT GGG TGC ATT GAA GCA TAC GCC TCT GGA ATG GCC TTG CAG AGG GAG GCA 1800 
Lys Lys Leu His Asp  GIu Asp Leu Leu Leu  Val  GIu Gly Met  Set Val  Pro Lys Asp GIu 620 
AAA AAG CTC CAT GAT GAG GAC CTG CTC TTG GTG GAA GGG AHG TCA GTG CCA AAA GAT GAG 1860 
Ala Val  Gly A/a Leu His Leu Ile Gln A la  A la  Lys Leu Gly ASh Ala Lys A la  Gln Ser 640 
GCT GTG GGT GCG CTC CAT CTC ATC CAA CCT GCG AAA CTT C43C AAT CCG AAG GCC CAG AGC 1920 
I le Leu Arg Thr A la  G ly  Thr  A la  Leu Gly Leu G ly  Val  Val  ASh  Ile Leu His  Thr Met  660 
ATC CHA AGA ACA OCT GGA ACA GCT TTG GGT CTT GGG GTT GTG AAC ATC CTC CAT ACC ATG 1980 
ASh Pro Set Leu Val  l le Leu  Ssr Gly  Val  Leu A la  Ser  His Tyr  I le His I le Val  Lys 680 
AAT CCC TCC CTT GTG ATC CTC TCC GGA GTC CTG CCC AGT CAC TAT ATC CAC ATT  GTC AAA 2040 
Asp Val  I le Arg Gln G ln  A la  Leu Ser Ser Val  Gln Asp  Val  Asp  Val  Val  Val  Ser Asp  780 
GAC GTC ATT  CGC CAG CAG GCC TTG TCC TCC GTG CAG GAC GTG GAT GTG GTG GTT TCG GAT 2100 
Leu Val  Asp Pro A la  Leu  Leu Gly A la  A la  Ser  Met  Val  Leu Asp  Tyr  Thr  Thr  Arg  Arg  720 
TTG GTT GAC CCC CCC CTG CTG GGT GCT GCC ACC ATG GTT CTG GAC TAC ACA ACA CGC AGG 2160 
l le Tyr  Ter  
ATC TAC TAG ACC TCC AGG AAC AGA CAT GGA CCT TCT CTC CAG AGC TCC TGA GTG GAA TCA 2220 
AGT TCT TGT CTT TAG GAT GAC CGT TTC TTA ACA ATC AAA TCT GGT ATT  GAA CTG CAG GTG 2280 
ACT TTG GCA GAG AAA TGT TTT CAC TTT ~GG TCT CCT CTT CCA GAG TCA CCT TTC CCC ACT 2340 
CCT ATT  TTT GTA GAT GCT ATT  CTT TCT GAT GTC TTC TTA CTA GGG GTC ATT  TTA GCT CAA 2400 
ACC CTG TAA GTT ACA GTC ACA ATT TTC TGT GCC AAA GCA GCT ACA ATA ATA GAG AGG gAG 2460 
CCT TCT TAG AAC TCT GCT TAC TAA TGT ATT AAT ACC ACT GAG ACC TTC AGG CCT TGC TGG 2520 
GAT ATC ACT TCA TCC TGA AGT TTG CAT TAA TAA TCC TTC CAG CCC GGG CAC AGT CCC TCA 2580 
CGC CTG TAA TCC CAG CAC TTT eGG AGG CCG AGG CGG GCG GAT CAC GAG GTC AGG AGA TCG 2640 
AGA CCG CCC TGG CTA ACA TCG TGA AAC ATG GTG AAA CCC CGT CTC TAC TAA AAA TAC AAA 2700 
AAA TTA GCT GGG TGT GGT GGC GGG TCC AGC TAC TCG GGA GGC TGA GGC AGG AGA ATG GCA 2760 
TGA ACC CCA GGC TGG AGT GCA GTG GCT CAA TGC AAC CTC TGC CCC CCG GGT TCG GTG ATT  2820 
CTC CTG CCT CAG CCT CTT GAG TGG CTG GGA TTG CGG GCA CAT GCA CCA CGC CCG CCT GAT 2880 
TTT TTT TTG TAH TTT TAG TGG ACA GGG TTH CAC CAT GTT GGC CAG GCT GGT CTT GAA CTC 2940 
CTG ACC TCA GGT GAT CCG CCC GCC HCT GCC TCC CAA GGT GCT GGA TTA CAG GHG TAA CCC 3000 
ATC ACA CCT GGC CCT AGT GAC AGG TTT TTA TGG GTA CTT TTA GAT GAT CTA AGA AAT CAT 3060 
GTG CAT ATA TCH TTC AGA TTT CTA TTT TGG AAA ATG AAG GTT TCT ACA ACA TAT TGT TTC 3120 
AGT GTT CAA ATA AAC TGA AGG ACT CAA CAT TAC ATT  TGA ACT ATA TCC TTC CTA GTG GGT 3180 
TAG TGT GAA AAA GAG TTT GGC TGA TTC CTA AAA CTC TGC CAG CCC TGC AGT AAT CTC CAG 3240 
GCC TGG TTA TTG TTC AGA CAT TCC ATG GTG ATT  CCH GGG AAG GAA GCT TGG CTG CTC AGT 3300 
TTC TGA GTC TGG GGT GAG ATA ATG TTC TGG AAG GAC ATC TGT TCT TTG GTG TAA TCT CHC 3360 
ATG GTG AAA TCT GCT CTG TAC ATC AGA CAA TTG CAT TGC TAC CAA GTT TCA TAC CAA ATA 3420 
TTT GAA AGG ATG GTA TTG AAT CTA AAC C~A ATA TTA GGT TTT TAT TAA ACT CAT GGG AAG 3480 
GCT AAT ATA TTC CAA CGT AAA TTA TTA CAT ATG GTT AAG TAA TTG CAT GTT /{AT TTA TTT 3540 
TAA TGT AAA TAT TTT TGT TAC TGT TCT GAG CCA AAT TCT AAA GAA AAA ATA AAH ACA TTT 3600 
CCT TGT TGA AAA AAA AAA 
Fig. 2. cDNA and deduced amino acid sequence of the human UDP-GlcNAc-2-epimerase/ManNAc kinase. The nucleotide position relative to 
+1 of the coding region and the numbered positions of the amino acid sequence are indicated on the right. 
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Germany) and the T7 sequencing kit (Pharmacia, Uppsala, Sweden), 
or with cycle sequencing and a LI-COR 4200 automatic sequencer 
(MWG-Biotech, Ebersberg, Germany). Both strands of all cDNA 
molecules were sequenced at least twice and the results analysed using 
the MacMolly Tetra software [23]. Nucleotides misincorporated by 
the Taq polymerase were identified by comparison of several inde- 
pendently obtained sequences. 
2.4. Northern blotting 
Commercially available Multiple Tissue Northern (MTN) blots 
(Clontech, Heidelberg, Germany) were used for expression analysis. 
The tissue Not carried 2 gg poly(A) + RNA from different human 
tissues: heart, brain, placenta, lung, liver, skeletal muscle, kidney 
and pancreas. The cell line blot carried 2 gg poly(A) + RNA from 
different human cancer cell lines: promyelocytic leukaemia HL-60, 
HeLa $3, chronic myelogenous leukaemia K-562, lymphoblastic leu- 
kaemia MOLT-4, Burkitt's lymphoma Raji, colorectal adenocarcino- 
ma SW480, lung carcinoma A549 and melanoma G361. Blot mem- 
branes were prehybridised in ExpressHyb solution (Clontech) for 3h 
at 42°C and hybridised with a 3zp-labelled probe. A random priming 
kit (Life Technologies, Karlsruhe, Germany) was used for labelling. 
Hybridisation was performed using ExpressHyb solution at 42°C. 
Filters were washed several times in 0.2% SSC, 0.1% SDS and sub- 
jected to phosphor imaging. 
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Fig. 3. Comparison of human, rat and mouse UDP-GlcNAc-2-epi- 
merase/ManNAc kinase with indicated protein consensus sequences. 
The amino acid position is indicated on the right. Identical amino 
acids are marked by ". Putatively phosphorylated amino acids are 
underlined and specified: protein consensus sequences for #: protein 
kinase C, *: casein kinase II, zx: cNMP-dependent kinase. Upper 
lane: human; middle lane: rat; lower lane: mouse. 
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Fig. 4. Tissue-specific expression analysis of human UDP-GlcNAc- 
2-epimerase/ManNAc kinase by Northern blot analysis. A riP-la- 
belled 500 bp coding region probe was hybridised to a MTN blot 
(Clontech, Heidelberg, Germany). Each lane carried 2 gg mRNA 
from various human tissues: (1) heart, (2) brain, (3) placenta, (4) 
lung, (5) liver, (6) skeletal muscle, (7) kidney, (8) pancreas. Hybrid- 
isation was done as described in Section 2.4. 
3. Results and discussion 
3.1. Nucleotide and amino acid sequence o f  the human 
UDP-GalNAc-2-epimerase/ManNAc kinase 
To isolate the cDNA for the human UDP-GlcNAc-2-epim- 
erase/ManNAc kinase we used a combination of RT-PCR, 5' 
RACE and cDNA phage library screening. Based on the pre- 
viously published sequence for the rat UDP-GlcNAc-2-epim- 
erase/ManNAc kinase we generated primer pairs to amplify 
cDNA fragments encoding the human homologous enzyme. 
These were cloned into the vector pCR 2.1. At least three 
independently obtained clones were sequenced. By this tech- 
nique we generated seven overlapping sequences by encoding 
the region +141 to +2031 bp. By the 5' RACE method we 
obtained two overlapping clones encoding the 5' end. Se- 
quencing revealed that these fragments encode the -47  to 
271 bp region. By screening a human liver cDNA library we 
obtained two clones encoding the region from +1400 to 3618 
and from +1932 to 3618, respectively. The strategy for cDNA 
isolation and cloning is shown in Fig. 1. 
The whole sequence for the UDP-GlcNAc-2-epimerase/ 
ManAc kinase is shown in Fig. 2. The open reading frame 
encodes 722 amino acids with a predicted molecular weight of 
79.4 kDa. Comparison of the human and rat coding sequen- 
ces revealed 82% sequence identity based on nucleotides and 
98% amino acid identity (Fig. 3). In the 3' untranslated region 
there is no significant similarity between human and rat. At 
the nucleotide position +3588 a polyadenylation consensus 
sequence was identified. Within the polypeptide there are sev- 
eral protein consensus equences for protein kinases, indicat- 
ing that the human UDP-GlcNAc-2-epimerase/ManNAc kin- 
ase might be phosphorylated on serine/threonine r sidues; no 
conserved consensus sequence for tyrosine phosphorylation 
could be identified. 
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Fig. 5. Expression analysis of human UDP-GlcNAc-2-epimerase/ 
ManNAc kinase in human cancer cell lines by Northern blot analy- 
sis. A 32p-labelled 500 bp coding region probe was hybridised to a 
MTN blot (Clontech, Heidelberg, Germany). Eachlane carried 2 [tg 
mRNA from various human cell lines: (1) promyelocytic leukaemia 
HL-60, (2) HeLa $3, (3) chronic myelogenous leukaemia K-562, 
(4) lymphoblastic leukaemia MOLT-4, (5) Burkitt's lymphoma Raji, 
(6) colorectal adenocarcinoma SW480, (7) lung carcinoma A549, 
(8) melanoma G361. Hybridisation was done as described in Section 
2.4. 
3.2. Expression of the human UDP-GlcNAc-2-eph~Terase/ 
ManNAc khulse 
The tissue-specific expression of the human UDP-GlcNAc-  
2-epimerase/ManAc kinase was examined by Northern blot 
analysis using poly(A) + RNA from different tissues (Fig. 4). 
Hybridisation with a coding region probe indicated that the 
corresponding mRNA migrates as a single 5.2 kb band. In 
contrast, the corresponding main band of rodent mRNA is 
3 kb in size. An additional mRNA population with a size 
of ~6 kb is found in rodent [14] but is missing in human 
mRNA.  This indicates that humans possess one splice variant. 
The mRNA was detected in all human tissues tested, and the 
highest expression occurred in liver and placenta. The high 
mRNA level in liver is consistent with the high enzyme activ- 
ity in this organ. The high expression in placenta indicates its 
essential role during development. This is supported by the 
detection of the enzyme in the early stages of mouse embryo- 
genesis [15]. By analysing mRNA we could show that the 
UDP-GlcNAc-2-epimerase/ManNAc kinase is differentially 
expressed by human cancer cell lines. The enzyme is strongly 
expressed in cervix carcinoma-derived HeLa cells and weakly 
expressed in lymphoblastic leukaemia MOLT-4 cells (Fig. 5). 
Recently, the important role of the UDP-GalNAc-2-epimer- 
ase as a regulator of cell surface glycoconjugate sialylation in 
haematopoietic cell lines was demonstrated [17]. Whether the 
enzyme is functionally relevant for the progression of carcino- 
genesis remains to be clarified in a separate study. 
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